Can GLP-1 Medications Affect Your Disability Insurance Underwriting? - RR Ep 21 episode artwork

EPISODE · Jul 29, 2026 · 8 MIN

Can GLP-1 Medications Affect Your Disability Insurance Underwriting? - RR Ep 21

from The Responsible Resident · host Amber Stitt

Send us Fan MailCan taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication affect your disability insurance application? In this episode of The Responsible Resident, disability insurance expert Amber Stitt explains how disability insurance underwriters are evaluating GLP-1 medications, weight loss, treatment stability, and medical follow-up for physicians applying for coverage.GLP-1 medications have transformed the treatment of obesity, type 2 diabetes, and metabolic conditions, but taking one does not automatically mean higher disability insurance premiums, exclusions, or postponement. Instead, underwriters look at the bigger health picture, including why the medication was prescribed, treatment response, follow-up care, related medical conditions, and whether weight loss has established a stable baseline.Amber also explains why underwriters may want approximately 12 months of weight stability before giving full credit for a lower weight and why consistent medical documentation can be important during disability insurance underwriting.Whether you're a medical student, resident, fellow, or attending physician, this episode provides practical insight into GLP-1 medications, physician disability insurance underwriting, weight-loss medications, and the importance of timing and stability when applying for coverage.📻 Thank you for tuning in to The Responsible Resident!To Download the FREE Medical Professionals Blueprint:StittStrategies.com/BlueprintIf you would like a free quote, please contact us at: mddisabilityquotes.com/responsible-residentAmber Stitt is a disability insurance specialist with over 15 years of experience helping physicians protect their income and make informed financial decisions. As the host of The Responsible Resident, she brings a structured, education-first approach to topics like disability insurance, underwriting, and income protection, areas often overlooked during medical training. 🔗 Connect with host, Amber Stitt, on Social Media:AMBER’S INSTAGRAMAMBER’S LINKEDINAMBER’S FACEBOOK📲 Be sure to visit the Stitt Strategies website:www.StittStrategies.com🎬 And remember, let's take action today!!!

Episode metadata supplied by the publisher feed · Published Jul 29, 2026

Embed this episode

Send us Fan Mail Can taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication affect your disability insurance application? In this episode of The Responsible Resident, disability insurance expert Amber Stitt explains how disability insurance underwriters are evaluating GLP-1 medications, weight loss, treatment stability, and medical follow-up for physicians applying for coverage. GLP-1 medications have transformed the treatment of obesity, type 2 diabetes, and metabolic ...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Can GLP-1 Medications Affect Your Disability Insurance Underwriting? - RR Ep 21

0:00 8:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Responsible Resident?

This episode is 8 minutes long.

When was this The Responsible Resident episode published?

This episode was published on July 29, 2026.

Can I download this The Responsible Resident episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!